BPC-157 is a synthetic peptide derived from a larger protective compound found naturally in the human body
When stratified by comparator groups, the pooled estimate was most favorable in monotherapy trials versus placebo (SMD 2.41, 95% CI 4.43 to 0.39), whereas the add-on designs versus the same background treatment (SMD 0.65, 95% CI 1.85 to 0.55), head-to-head comparisons versus another drug (SMD 0.19, 95% CI 0.84 to 0.45), and add-on designs versus placebo (SMD 0.65, 95% CI 1.35 to 0.06) showed more modest estimates and did not provide clear evidence of a between-group difference overall (p=0.21)
Results were normalized per cell number for medium samples, or per total protein concentration (Bradford assay, Bio-Rad, Hercules, CA, USA) for protein extraction samples
SLC7A11 can also be inactivated by AMPK-mediated phosphorylation of BECN1, which leads to the formation of BECN1-SLC7A11 complex (Kang et al., 2018
This distinction is critical, as even a biologically promising compound may become clinically harmful when delivered through nonstandardized formulations
10.1016/j.bbrc.2007.05.054 20 GuanX.MackD